Actively Recruiting
Global Trial Comparing Intra-arterial Thrombolysis with Tenecteplase or Alteplase Versus No Thrombolysis After Endovascular Thrombectomy for Acute Ischemic Stroke
Led by University of Calgary · Updated on 2026-10-21
1500
Participants Needed
13
Research Sites
12 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness of targeted intra-arterial thrombolysis using either tenecteplase or alteplase compared to no intra-arterial thrombolysis in patients with Acute Ischemic Stroke AIS who undergo endovascular thrombectomy EVT. This study is a randomized, controlled trial designed to address the issue of incomplete reperfusion following EVT, which is a major factor in poor recovery despite successful thrombectomy. The trial aims to generate definitive evidence on the safety and benefit of intra-arterial thrombolysis in a globally representative patient population. Participants are randomly assigned to receive either a single dose of local intra-arterial thrombolysis with tenecteplase 0.0625 mgkg, max 6.25 mg or alteplase 0.225 mgkg, max 20 mg immediately after EVT, plus standard care, or standard care alone without intra-arterial thrombolysis. The dose of thrombolysis may be increased if interim analyses suggest futility at initial doses. The choice of thrombolytic agent depends on local availability. Randomization is stratified by countryregion and the thrombolytic agent used. During the study, participants are followed for 90 days or until death if earlier. Researchers assess functional outcomes using the modified Rankin Scale mRS through centralized telephone or online interviews conducted by personnel blinded to treatment allocation. Additional measures include monitoring mortality rates at 90 days. The trials primary outcome is the reduction of functional dependence on the mRS scale at day 90. Safety and efficacy data will be collected throughout the follow-up period to inform clinical practice.
CONDITIONS
Brief Title
ACT-GLOBAL IA Thrombolysis(ACT-REACT-004)Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632
Research Team
B
Bijoy K Menon, MD
C
Craig Anderson, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here